Search

Displaying results 351 - 360 of 825 in total
  1. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]

  2. Drug

    Thiosulfuric acid

    go.drugbank.com/drugs/DB09499
    ApprovedInvestigational

    Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, ...

  3. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    [A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades.

  4. Drug

    Elgemtumab

    go.drugbank.com/drugs/DB15430
    Investigational

    Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

  5. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B.

  6. Drug

    LX-7101

    go.drugbank.com/drugs/DB16009
    Investigational

    LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).

  7. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but...

  8. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...

  9. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...

  10. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).